CANINE ATOPIC DERMATITIS TREATMENT DRUGS MARKET ANALYSIS

Canine Atopic Dermatitis Treatment Drugs Market Size and Trends

The canine atopic dermatitis treatment drugs market is estimated to be valued at USD 1,494.4 Mn in 2024 and is expected to reach USD 2,936.6 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.1% from 2024 to 2031.

To learn more about this report, request sample copy

The canine atopic dermatitis treatment drugs market is expected to grow steadily over the forecast period. The increasing prevalence of atopic dermatitis in dogs and rising pet care expenditure are contributing to the growth of this market. The market is expected to witness a positive trend over the forecast period. There is a high unmet need for more effective treatments for canine atopic dermatitis. Several pipeline drugs are under development which could become blockbuster products if clinical trials are successful. In addition, growing awareness about atopic dermatitis and its available treatments options among pet owners will continue to support market expansion.

Rising Research & Development Activities and Increasing Number of Approvals from Regulatory Agencies

Pharmaceutical companies are actively investing in research and development to create advanced and highly effective treatment options for canine atopic dermatitis. They are focusing on innovating drug delivery systems, refining formulation techniques, and identifying new therapeutic targets. These efforts have led to the development of enhanced medications, offering improved outcomes for the management of the condition. For instance, in July 2021, Virbac Corporation, a France-based company dedicated to animal health, announced the availability of CYCLAVANCE (cyclosporine oral solution) USP MODIFIED, an oral solution for the control of atopic dermatitis in dogs. While veterinarians in the U.S. are familiar with cyclosporine in capsule form, CYCLAVANCE oral solution represents the first U.S. U.S. Food and Drug Administration approved liquid cyclosporine for dogs in the U.S.

Canine atopic dermatitis (AD) is a complex disease with multiple contributing factors. It is characterized as an inflammatory and pruritic allergic skin condition that often occurs in dogs with a genetic predisposition and is associated with the production of immunoglobulin E (IgE) in response to environmental allergens. The most common and clinically significant feature of CAD is moderate to severe pruritus, which is accompanied by, and typically precedes, erythema, erythematous macular and/or popular eruptions, self-induced alopecia, excoriations, hyperpigmentation, and lichenification. According to the American College of Veterinary Dermatology (ACVD), the estimated prevalence of AD in dogs is approximately 10-15%. Furthermore, as per the data published in Blackmores, a leading natural health company, in September 2020, atopic dermatitis is the second most prevalent allergic skin disease in dogs. Golden Retriever, German Shepherd, Labrador, and Pug breeds have been proven to be the most prone to canine atopic dermatitis. Canine AD is a chronic condition that significantly affects a dog's quality of life. Itchy and inflamed skin can cause discomfort, pain, and distress for affected dogs. As pet owners prioritize their pets' well-being and seek to improve their quality of life, they are more inclined to explore and invest in effective treatments. Thus, emphasis on improving the quality of life for dogs with AD drives the market growth.